PMID- 38008954
OWN - NLM
STAT- MEDLINE
DCOM- 20240125
LR  - 20240125
IS  - 1744-7607 (Electronic)
IS  - 1742-5255 (Linking)
VI  - 19
IP  - 12
DP  - 2023 Dec
TI  - A systematic review on the clinical pharmacokinetics of vildagliptin in healthy 
      and disease populations.
PG  - 991-1003
LID - 10.1080/17425255.2023.2288252 [doi]
AB  - INTRODUCTION: Vildagliptin, a dipeptidyl peptidase-4 inhibitor, is indicated to 
      cure type 2 diabetes mellitus (T2DM). This systematic literature search aims to 
      assess the current knowledge about the clinical pharmacokinetics (PK) of 
      vildagliptin to provide recommendations for clinical use to prevent the harmful 
      effects of this drug. METHODS: The PubMed, Science Direct, EBSCO, Cochrane 
      Central Register of Controlled Trials, and Google Scholar databases were screened 
      for articles related to the clinical PK of vildagliptin using systematic search 
      strategies. RESULTS: The literature search identified 2118 records, among which 
      28 were subsumed in this systematic review that fulfilled the inclusion 
      standards. CONCLUSIONS: This systematic review can help dose optimization among 
      critically ill patients (e.g. renal impairment) without exposing them to the 
      drug's toxic effects.
FAU - Pasha, Mahnoor
AU  - Pasha M
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya 
      University, Multan, Pakistan.
FAU - Zamir, Ammara
AU  - Zamir A
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya 
      University, Multan, Pakistan.
FAU - Ashraf, Waseem
AU  - Ashraf W
AD  - Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, 
      Multan, Pakistan.
FAU - Imran, Imran
AU  - Imran I
AD  - Department of Pharmacology, Faculty of Pharmacy, Bahauddin Zakariya University, 
      Multan, Pakistan.
FAU - Saeed, Hamid
AU  - Saeed H
AD  - Allama Iqbal Campus, University College of Pharmacy, Lahore, Pakistan.
FAU - Rehman, Anees Ur
AU  - Rehman AU
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya 
      University, Multan, Pakistan.
FAU - Aziz, Majid
AU  - Aziz M
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya 
      University, Multan, Pakistan.
FAU - Alqahtani, Faleh
AU  - Alqahtani F
AD  - Department of Pharmacology and Toxicology, College of Pharmacy, King Saud 
      University, Riyadh, Saudi Arabia.
FAU - Rasool, Muhammad Fawad
AU  - Rasool MF
AUID- ORCID: 0000-0002-8607-8583
AD  - Department of Pharmacy Practice, Faculty of Pharmacy, Bahauddin Zakariya 
      University, Multan, Pakistan.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20240112
PL  - England
TA  - Expert Opin Drug Metab Toxicol
JT  - Expert opinion on drug metabolism & toxicology
JID - 101228422
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - I6B4B2U96P (Vildagliptin)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects/pharmacokinetics
MH  - *Vildagliptin/adverse effects/pharmacokinetics
OTO - NOTNLM
OT  - Pharmacokinetics
OT  - peak plasma concentration
OT  - renal impairment
OT  - systematic review
OT  - vildagliptin
EDAT- 2023/11/27 06:47
MHDA- 2024/01/15 12:43
CRDT- 2023/11/27 03:38
PHST- 2024/01/15 12:43 [medline]
PHST- 2023/11/27 06:47 [pubmed]
PHST- 2023/11/27 03:38 [entrez]
AID - 10.1080/17425255.2023.2288252 [doi]
PST - ppublish
SO  - Expert Opin Drug Metab Toxicol. 2023 Dec;19(12):991-1003. doi: 
      10.1080/17425255.2023.2288252. Epub 2024 Jan 12.